1st Patient Treated in Phase 1 Trial of ATG-019 for Lymphoma, Solid Tumors
News
The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or ... Read more